Cerus, headquartered in Concord, California, focuses on developing the INTERCEPT Blood System to enhance blood safety by reducing pathogens in transfusion blood components. The company employs 288 people and specializes in various blood products.
Cerus (CERS) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cerus's actual EPS was -$0.01, beating the estimate of -$0.01 per share, resulting in a 15.97% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
